Fernández García, AitorZhou, YingGarcía Alonso, MercedesAndrango, Henry D.Poyales Galán, FranciscoGarzón Jiménez, Nuria2023-06-162023-06-162019-110165-570110.1007/s10792-019-01232-3https://hdl.handle.net/20.500.14352/5978Received: 7 august 2019; Accepted: 16 november 2019Purpose: To evaluate medium-term clinical outcomes with microstent XEN® 45 Gel Stent (Allergan Dublin, Ireland) for treatment of primary open-angle glaucoma (POAG). Material and methods: This is a retrospective, descriptive and observational study involving 93 eyes from 63 patients who had undergone POAG surgery with a XEN® 45 Gel Stent implantation and had been followed up and controlled between 12 and 36 months. Results: IOP dropped from 18.23 ± 5.00 mmHg pre-op to 14.16 ± 2.14, 14.47 ± 2.16 and 14.63 ± 1.91 at 1, 2 and 3 years after surgery (p = 0.000, 0.000 and 0.001) consecutively. Mean number of medications dropped from 1.87 ± 0.94 preoperatively to 0.31 ± 0.69, 0.34 ± 0.63 and 1.00 ± 0.88 (p = 0.000, 0.000 and 0.017) at 12, 24 and 36 months. Mean visual field deviation values never turned out to be significant for any of the follow-up visit data. A total of 94.6% of the surgical procedures turned out to be complication-free. In one surgery, the procedure failed and 18 months later other device was implanted. Conclusion: POAG surgical procedures with XEN® 45 Gel Stent implants are a safe and effective treatment approach.engjournal articlehttps://doi.org/10.1007/s10792-019-01232-3https://link.springer.com/article/10.1007%2Fs10792-019-01232-3open access617.7-007.681-089GlaucomaMIGSXen45CirugíaOftalmología3213 Cirugía3201.09 Oftalmología